Toggle menu

SNAP40 Study

Start date:
September 2017
End date:
December 2017
Co-ordinated by:
EMERGE
Main trial site:
Royal Infirmary of Edinburgh

SNAP40-ED: Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the Emergency Department.

SNAP40 is a device that monitors vital signs. It is small, portable and has no leads or wires, allowing for patients vital signs to be continuously monitored anywhere in the department. The device is smaller than most mobile phones, and is held within a blue casing attached to an armband (please see image). When fitted to a patient’s arm, the device will continuously monitor their vital signs whilst they are in the Emergency Department.

SNAP40 uses artificial intelligence algorithms to analyse data provided by its sensors in order to recognise indicators of health deterioration. The raw data collected by the sensors is converted into vital signs, which are analysed for signs of deterioration. An alert will be sent to staff if the device detects any signs of deterioration in the patient’s readings.

Funding: SNAP40

Sponsor: SNAP40, Forth Street, Edinburgh (UK)

Setting: This is a single centre study being co-ordinated from Edinburgh.

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Alison Grant

Senior Research Nurse

Mary Morrissey

Senior Research Nurse

Related news

Exciting new trial: SNAP40

Exciting new trial: SNAP40

10 Apr 2017 | Megan McGrath

EMERGE will soon begin recruitment to the new SNAP40 trial which will compare the new SNAP40 device with standard monitoring devices in the Emergency Department.

Read more

More EMERGE Trials

PRIEST

Pandemic Respiratory Infection Emergency System Triage

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.